Vaginal cancer

Description

Carcinoma of the vagina occurs in less than 2% of women with pelvic malignant tumors. Squamous carcinoma is the most common type of vaginal cancer. The human papillomavirus (HPV) is strongly associated with vaginal cancer. Vaginal cancer occurs most often in the upper third of the vagina (51%), 30% are found in the lower third, and 19% in the middle third. Vaginal cancer can present as an elevated lesion growing out from the epithelial surface or an ulcer-like, shallow depression. Definitive diagnosis is determined by biopsy.

Signs and symptoms

Most vaginal cancers do not cause signs or symptoms early on. When vaginal cancer does cause symptoms, they may include:

• Vaginal discharge or abnormal bleeding
• Unusually heavy flow of blood
• Bleeding after menopause
• Bleeding between periods; or any other
• Bleeding that is longer than normal
• Blood in the stool or urine
• Frequent or urgent need to urinate
• Feeling constipated
• Pain during sexual intercourse
• A lump or growth in the vagina that can be felt. Enlarged pelvic lymph nodes can sometimes be palpated.

Risk factors

• Prenatal exposure to diethylstilbestrol
• Infection with human papillomavirus (HPV) type 16
• Infection with human immunodeficiency virus (HIV) type 1
• Previous history of cervical cancer
• Smoking
• Chronic vulvar itching or burning

Types

There are two primary types of vaginal cancer: squamous-cell carcinoma and adenocarcinoma.

• Squamous-cell carcinoma of the vagina arises from the squamous cells (epithelium) that line the vagina. This is the most common type of vaginal cancer. It is found most often in women aged 60 or older.
• Vaginal adenocarcinoma arises from the glandular (secretory) cells in the lining of the vagina. Adenocarcinoma is more likely to spread to the lungs and lymph nodes.
• Clear cell adenocarcinoma occurs in a small percentage of women (termed "DES-Daughters") born between 1938 and 1973 (later outside the United States) that were exposed to the drug diethylstilbestrol (DES) in utero. DES was prescribed to 5 to 10 million mothers period to prevent possible miscarriages and premature births. Typically, women develop DES-related adenocarcinoma before age 30, but increasing evidence suggests possible effects or cancers (including other forms of vaginal glandular tumors) at a later age. DES-exposure in women is also linked to various infertility and pregnancy complications. Daughters exposed to DES in utero may also have an increased risk of moderate/severe cervical squamous cell dysplasia and an increased risk of breast cancer. Approximately one in 1,000 (0.1%) DES daughters will be diagnosed with clear cell adenocarcinoma. The risk is virtually non-existent among premenopausal women not exposed to DES.
• Vaginal germ cell tumors (primarily teratoma and endodermal sinus tumor) are rare. They are usually found in infants and children.
• Sarcoma botryoides, a rhabdomyosarcoma, is also found most often in infants and children.
• Vaginal melanoma, a melanoma that appears in the vagina.

File:Diagram showing stage 1 vaginal cancer CRUK 194.svg|Stage 1 vaginal cancer File:Diagram showing stage 2 vaginal cancer CRUK 210.svg|Stage 2 vaginal cancer File:Diagram showing stage 3 vaginal cancer CRUK 223.svg|Stage 3 vaginal cancer File:Diagram showing stage 4A vaginal cancer CRUK 237.svg|Stage 4A vaginal cancer File:Diagram showing stage 4B vaginal cancer CRUK 240.svg|Stage 4B vaginal cancer

Diagnosis and screening

Routine vaginal cancer screening, including routine surveillance imaging such as ultrasound or MRI, is not recommended for women who do not have symptoms. Imaging without indications is discouraged because it is unlikely to detect a recurrence or improve survival, and because it has its own costs and side effects. Several tests are used to diagnose vaginal cancer, including:

• Physical exam and history
• Pelvic exam
• Biopsy
• Colposcopy

MRI provides visualization of the extent of vaginal cancer. Other sources of cancer tissue such as the urethra or the cervix must be ruled out before a diagnosis of vaginal cancer is made. Vaginal cancer cannot be detected through cervical pap smears.

Classification

Staging: The International Federation of Gynecology and Obstetrics utilizes the Tumor, Node, Metastasis (TNM) method of staging vaginal cancer. The clinical staging of the most common form of primary vaginal cancer, squamous cell carcinoma, is outlined below.

• Stage I - Tumor confined to the vagina
• Stage II - Tumor invading tissue near the vagina, but has not spread to the pelvic wall
• Stage III- Tumor invading pelvic sidewall or interfering with renal function, obstructing the ureter to cause hydronephrosis.
• Stage IV - Tumor invading mucosa of nearby pelvic organs, including bladder or rectum, or has spread beyond the pelvis.

Management

Historically, the combination of external-beam radiation therapy (EBRT) has been the most common treatment for vaginal cancer. In the early stages of vaginal cancer, surgery also has some benefit. This management and treatment is less effective for those with advanced stages of cancer, but works well in early stages with high rates of cure. Advanced vaginal cancer only has a 5-year survival rate of 52.2%, 42.5% and 20.5% for patients with stage II, III, and IVa disease. Newer treatments for advanced stages of ovarian cancer have been developed. These utilize concurrent carboplatin plus paclitaxel, EBRT and high-dose-rate interstitial brachytherapy (HDR-ISBT).

When the chance of surgical removal of all cancerous tissue is very low or when the surgery has a chance of damaging the bladder, vagina, or bowel, radiation therapy is used. When a tumor is less than 4 cm in diameter, radiation therapy provides excellent results. In these instances, the 5-year survival rate is over 80%. Treatments are individualized due to the rarity of vaginal cancer studies.

File:Diagram showing a wide local excision for vaginal cancer CRUK 087.svg|A local surgery to remove vaginal cancer File:Diagram showing a radical hysterectomy for vaginal cancer CRUK 075.svg|A radical hysterectomy to treat vaginal cancer without reconstruction File:Diagram showing a radical hysterectomy with a reconstructed vagina CRUK 076.svg|A radical hysterectomy for vaginal cancer with reconstruction of the vagina using other tissues

Epidemiology

Cancer of the vagina is rare and is only 2% of all gynecological cancers and less than 0.5% of all cancers in women. Estimated new cases in the United States in 2017 are 4,810. Deaths from vaginal cancer during the same time were 1,240. It is more common in older women.

In the UK, 254 cases of vaginal cancer were identified in 2014. Deaths from vaginal cancer in this period were 110. Out of those with vaginal cancer, 53% are related to HPV infection.

Research

Clinical trials

• Because vaginal cancer is so rare, there have been very few phase three clinical trials studying treatments specifically targeting vaginal cancer. There is an ongoing phase three trial studying the efficacy of the drug triapine to treat vaginal cancer. There are currently several phase one and two clinical trials underway to study the efficacy of new gynecological cancer treatment regimens, which include treatment for vaginal cancer.

References

References

1. (January 2021). "Cancer Statistics, 2021". CA: A Cancer Journal for Clinicians.
2. Berek, JS. (2015). "Berek and Hacker's Gynecologic Oncology, 6th ed.". Lippincott Williams & Wilkins.
3. (1966-12-15). "Primary carcinoma of the vagina". American Journal of Obstetrics and Gynecology.
4. (August 1982). "Neoplasms of the vagina following cervical carcinoma". Gynecologic Oncology.
5. (1971-04-15). "Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women". The New England Journal of Medicine.
6. (1971-07-05). "Carcinoma of the vagina". JAMA.
7. (1998-09-01). "The National Cancer Data Base report on cancer of the vagina". Cancer.
8. (2013-08-01). "Evaluation of Vaginal Cysts and Masses by 3-Dimensional Endovaginal and Endoanal Sonography". Journal of Ultrasound in Medicine.
9. (10 September 2015). "Symptoms {{!}} Vaginal cancer {{!}} Cancer Research UK".
10. (2017). "List of Classifications by cancer sites with sufficient or limited evidence in humans, Volumes 1 to 120 a". World Health Organization, International Agency for Research on Cancer.
11. (December 2016). "Vaginal and Vulvar Cancer". Centers for Disease Control and Prevention.
12. "About DES". Centers for Disease Control and Prevention.
13. "Known Health Effects for DES Daughters". Centers for Disease Control and Prevention.
14. (February 2014). "Five Things Physicians and Patients Should Question". Society of Gynecologic Oncology.
15. (2021-08-23). "What Should I Know About Screening for Vaginal and Vulvar Cancers? {{!}} CDC".
16. (2013-05-06). "Perez and Brady's principles and practice of radiation oncology".
17. (April 2016). "A Common Clinical Dilemma: Management of Abnormal Vaginal Cytology and Human Papillomavirus Test Results". Journal of Lower Genital Tract Disease.
18. (May 2009). "Factors affecting risk of mortality in women with vaginal cancer". Obstetrics and Gynecology.
19. (2016). "Treatment of early stage vaginal cancer with EBRT and MRI-based intracavitary brachytherapy: A retrospective case review". Gynecologic Oncology Reports.
20. (2015-01-01). "First two cases of primary carcinoma of the vagina successfully treated with concurrent weekly carboplatin plus paclitaxel, external beam radiotherapy and high-dose-rate interstitial brachytherapy: A case report and published work review". Journal of Obstetrics and Gynaecology Research.
21. (9 February 2017). "Vaginal Cancer Treatment". National Institutes of Health, National Cancer Institute.
22. "Vaginal cancer {{!}} Vaginal cancer {{!}} Cancer Research UK".
23. (2015-05-14). "Vaginal cancer statistics". Cancer Research UK.
24. (2015-05-15). "Vaginal cancer risk factors". Cancer Research UK.
25. (March 2012). "Vaginal cancer". Critical Reviews in Oncology/Hematology.
26. "A Study of Combination Radiation Therapy and Cisplatin with or without Triapine for Treating Patients with Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer".
27. M.D. Anderson Cancer Center. (2020-12-01). "A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers".
28. (2019-11-01). "Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial". Journal of Clinical Oncology.